Seres Therapeutics, Inc. (MCRB) stock
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.41+0.00 (0.00%)
Close on Nov 17, 2026Market cap $14.02MP/E –Yield –
Seres Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Seres Therapeutics's total assets was $101.59M at Jun 30, 2026. For fiscal 2025 it was $138.19M, down 1.2% from the year before. Over ten years it grew -4.4% a year on average. The highest annual figure on record is $358.60M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $138.19M | -1.2% |
| FY2024 | Dec 31, 2024 | $139.81M | -61.0% |
| FY2023 | Dec 31, 2023 | $358.60M | +2.8% |
| FY2022 | Dec 31, 2022 | $348.78M | -1.7% |
| FY2021 | Dec 31, 2021 | $354.86M | +3.5% |
| FY2020 | Dec 31, 2020 | $342.94M | +158.9% |
| FY2019 | Dec 31, 2019 | $132.44M | +9.9% |
| FY2018 | Dec 31, 2018 | $120.47M | -36.4% |
| FY2017 | Dec 31, 2017 | $189.52M | -30.5% |
| FY2016 | Dec 31, 2016 | $272.65M | +25.7% |
| FY2015 | Dec 31, 2015 | $216.90M | +84.8% |
| FY2014 | Dec 31, 2014 | $117.35M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $101.59M | -29.4% |
| Q1 FY2026 | Mar 31, 2026 | $117.62M | -28.4% |
| Q4 FY2025 | Dec 31, 2025 | $138.19M | -1.2% |
| Q3 FY2025 | Sep 30, 2025 | $143.47M | -19.7% |
| Q2 FY2025 | Jun 30, 2025 | $143.80M | -55.3% |
| Q1 FY2025 | Mar 31, 2025 | $164.18M | -51.9% |
| Q4 FY2024 | Dec 31, 2024 | $139.81M | -61.0% |
| Q3 FY2024 | Sep 30, 2024 | $178.74M | -51.4% |
| Q2 FY2024 | Jun 30, 2024 | $321.73M | -20.8% |
| Q1 FY2024 | Mar 31, 2024 | $341.26M | +26.3% |
| Q4 FY2023 | Dec 31, 2023 | $358.60M | +2.8% |
| Q3 FY2023 | Sep 30, 2023 | $367.70M | +17.9% |
| Q2 FY2023 | Jun 30, 2023 | $406.39M | +48.8% |
| Q1 FY2023 | Mar 31, 2023 | $270.19M | -15.5% |
| Q4 FY2022 | Dec 31, 2022 | $348.78M | -1.7% |
| Q3 FY2022 | Sep 30, 2022 | $311.87M | -21.3% |
| Q2 FY2022 | Jun 30, 2022 | $273.20M | +1.3% |
| Q1 FY2022 | Mar 31, 2022 | $319.89M | +4.6% |
| Q4 FY2021 | Dec 31, 2021 | $354.86M | +3.5% |
| Q3 FY2021 | Sep 30, 2021 | $396.29M | +11.3% |
| Q2 FY2021 | Jun 30, 2021 | $269.65M | +167.8% |
| Q1 FY2021 | Mar 31, 2021 | $305.70M | +176.3% |
| Q4 FY2020 | Dec 31, 2020 | $342.94M | +158.9% |
| Q3 FY2020 | Sep 30, 2020 | $356.20M | +186.9% |
| Q2 FY2020 | Jun 30, 2020 | $100.68M | -31.1% |
| Q1 FY2020 | Mar 31, 2020 | $110.62M | +3.3% |
| Q4 FY2019 | Dec 31, 2019 | $132.44M | +9.9% |
| Q3 FY2019 | Sep 30, 2019 | $124.15M | +13.9% |
| Q2 FY2019 | Jun 30, 2019 | $146.09M | +9.9% |
| Q1 FY2019 | Mar 31, 2019 | $107.04M | -32.9% |
| Q4 FY2018 | Dec 31, 2018 | $120.47M | -36.4% |
| Q3 FY2018 | Sep 30, 2018 | $109.04M | -48.5% |
| Q2 FY2018 | Jun 30, 2018 | $132.95M | -38.5% |
| Q1 FY2018 | Mar 31, 2018 | $159.43M | -34.9% |
| Q4 FY2017 | Dec 31, 2017 | $189.52M | -30.5% |
| Q3 FY2017 | Sep 30, 2017 | $211.88M | -28.8% |
| Q2 FY2017 | Jun 30, 2017 | $216.34M | – |
| Q1 FY2017 | Mar 31, 2017 | $244.85M | – |
| Q4 FY2016 | Dec 31, 2016 | $272.65M | – |
| Q3 FY2016 | Sep 30, 2016 | $297.51M | – |
See a number that looks wrong?